1. What information is needed to inform medicines benefits decisions? Tuesday 30 September Topic C1

2. What are key performance indicators of medicines benefits from different stakeholders’ perspectives? Patients – Client satisfaction with actual care (survey) Providers – % Compliance of claims with STGs/ protocol – % patients with intended outcomes Suppliers Scheme/payer – % of (insured) population actually receiving medicines cover – % population with certain disease who get their medicines funded by scheme – % allocation of funds by therapeutic categories – % of budget compared to spending – Relevance of the package vs disease burden – % of non-adherence reported – % fraud reported – Value for money put in benefit package

3. How can indicators be created using existing data in countries and systems? Value for money put in benefit package: – e.g.HIV outcome measure/money spent – # Transmissions averted – # years of life saved (life expectancy) – Quality of life – Reduction in population viral load – # of HIV related hospitalisation – Mortality 2 nd specific CD and NCD – Avoiding complication – # new infections per year Morale obligation for HIV, still looking for value for money? What is the threshold used to determine cost effectiveness ratio

4. What are successes and challenges in using existing data to inform medicines benefit design, implementation, and adaptation? In some countries, no easy access to money spent SA: conditional grant